Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Non-Current Deffered Revenue (2021 - 2024)

Werewolf Therapeutics (HOWL) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $431000.0 as the latest value for Q1 2024.

  • Quarterly Non-Current Deffered Revenue fell 64.08% to $431000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $431000.0 through Mar 2024, down 64.08% year-over-year, with the annual reading at $433000.0 for FY2023, 61.61% down from the prior year.
  • Non-Current Deffered Revenue for Q1 2024 was $431000.0 at Werewolf Therapeutics, roughly flat from $433000.0 in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $1.3 million in Q1 2021, with the low at $11000.0 in Q3 2021.
  • Average Non-Current Deffered Revenue over 4 years is $675363.6, with a median of $588000.0 recorded in 2023.
  • The sharpest move saw Non-Current Deffered Revenue skyrocketed 4544.44% in 2022, then plummeted 64.08% in 2024.
  • Over 4 years, Non-Current Deffered Revenue stood at $11000.0 in 2021, then skyrocketed by 10154.55% to $1.1 million in 2022, then crashed by 61.61% to $433000.0 in 2023, then dropped by 0.46% to $431000.0 in 2024.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $431000.0, $433000.0, and $588000.0 for Q1 2024, Q4 2023, and Q3 2023 respectively.